Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study (PROFILE)
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring condition of the lungs the cause of which is unknown.There are currently no effective treatments for IPF and the condition tends to cause progressive disability and death with an average survival of 3.5 years from diagnosis. The condition is responsible for the deaths of 4000 people per year in the UK. At present the definite diagnosis of IPF rests on the identification of a specific pattern of fibrosis when a section of fibrotic lung tissue is examined under a microscope. Unfortunately, the process of obtaining a lung biopsy requires an operation and is not with out risk. The investigators hope to identify specific markers in the blood and lungs of patients with IPF that will enable the condition to be diagnosed without biopsy. Furthermore, the investigators hope to identify indicators(biomarkers) that will predict which patients have more aggressive and progressive disease and also to identify biomarkers that might be useful in identifying a response to treatment and might therefore be used in future clinical trials in IPF. As well as looking at markers in the blood and lungs the investigators also plan to assess the use of daily home lung function measurement and a computerised technique for analyzing lung sounds to see if these are investigations that are able to predict the development of worsening lung fibrosis.
Idiopathic Pulmonary Fibrosis
Idiopathic Non-specific Interstitial Pneumonitis
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE_Brompton)Study|
- Biomarker discovery [ Time Frame: 3 years ] [ Designated as safety issue: No ]Discover and validate novel biomarkers and gene expression profiles for use in subsequent clinical studies in patients with idiopathic pulmonary fibrosis.
- Study disease behaviour [ Time Frame: 3 years ] [ Designated as safety issue: No ]Prospectively evaluate longitudinal disease behavior in patients with IPF and other fibrotic lung diseases of unknown cause with a view to developing composite clinical endpoints for subsequent use in clinical studies in patients with pulmonary fibrosis.
- Differentiate IPF from NSIP [ Time Frame: 3 years ] [ Designated as safety issue: No ]Identify differences in the pathogenetic mechanisms involved in the development of different types of fibrosis in patients with fibrotic lung disease of unknown cause.
Biospecimen Retention: Samples With DNA
Whole blood, serum, bronchoalveolar lavage, surgical lung biopsy (when clinically indicated)
|Study Start Date:||September 2010|
|Estimated Study Completion Date:||September 2016|
|Estimated Primary Completion Date:||September 2015 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01110694
|Contact: Toby M Maher, MB MSc PhD||+44(0)20 7352 8121 ext firstname.lastname@example.org|
|Royal Brompton Hospital||Recruiting|
|London, United Kingdom, SW3 6NP|
|Contact: Toby M Maher, MB MSc PhD +44(0)207 352 8121 ext 4188 email@example.com|
|Contact: Anne-Marie Russell, RGN +44(0)207 352 8121 ext 4923 firstname.lastname@example.org|
|Principal Investigator: Toby M Maher, MB MSc PhD|
|Principal Investigator:||Toby M Maher, MB PhD||Royal Brompton and Harefield Foundation NHS Trust|